Literature DB >> 11303075

Effects of cannabinoids on sympathetic and parasympathetic neuroeffector transmission in the rabbit heart.

B Szabo1, U Nordheim, N Niederhoffer.   

Abstract

Cannabinoids elicit marked cardiovascular responses. It is not clear how peripheral effects on the autonomic nervous system contribute to these responses. The aim of the present study was to characterize the peripheral actions of cannabinoids on the autonomic innervation of the heart. Experiments were carried out on pithed rabbits. In the first series of experiments, postganglionic sympathetic cardioaccelerator fibers were stimulated electrically. The synthetic cannabinoid receptor agonists WIN55212-2 (0.005, 0.05, 0.5, and 1.5 mg kg(-1) i.v.) and CP55940 (0.003, 0.03, 0.3, and 1 mg kg(-1) i.v.) dose dependently inhibited the electrically evoked cardioacceleration. The inhibition by WIN55212-2 (0.5 mg kg(-1) i.v.) was prevented by the CB(1) cannabinoid receptor antagonist SR141716A (0.5 mg kg(-1) i.v.). WIN55212-2 (0.5 mg kg(-1) i.v.) did not change the increase in heart rate evoked by injection of isoprenaline. In the second series of experiments, preganglionic vagal fibers were stimulated electrically. WIN55212-2 (0.005, 0.05, and 0.5 mg kg(-1) i.v.) and CP55940 (0.003, 0.03, and 0.3 mg kg(-1) i.v.) dose dependently inhibited the stimulation-evoked decrease in heart rate. The inhibition produced by WIN55212-2 (0.005, 0.05, and 0.5 mg kg(-1) i.v.) was antagonized by SR141716A (0.5 mg kg(-1) i.v.). The results indicate that cannabinoids, by activating CB(1) cannabinoid receptors, inhibit sympathetic and vagal neuroeffector transmission in the heart. The mechanism of the sympathoinhibition is probably presynaptic inhibition of noradrenaline release from postganglionic sympathetic neurons. The mechanism of the inhibition of vagal activity was not clarified: cannabinoids may have an inhibitory action on both pre- and postganglionic vagal neurons.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11303075

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  22 in total

Review 1.  Triphasic blood pressure responses to cannabinoids: do we understand the mechanism?

Authors:  Barbara Malinowska; Marta Baranowska-Kuczko; Eberhard Schlicker
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 2.  Latest advances in novel cannabinoid CB(2) ligands for drug abuse and their therapeutic potential.

Authors:  Peng Yang; Lirong Wang; Xiang-Qun Xie
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

3.  Differential effects of cannabinoid CB1 inverse agonists and antagonists on impulsivity in male Sprague Dawley rats: identification of a possibly clinically relevant vulnerability involving the serotonin 5HT1A receptor.

Authors:  Peter J McLaughlin; Julia E Jagielo-Miller; Emily S Plyler; Kerry K Schutte; V Kiran Vemuri; Alexandros Makriyannis
Journal:  Psychopharmacology (Berl)       Date:  2017-02-01       Impact factor: 4.530

Review 4.  Cannabimimetic phytochemicals in the diet - an evolutionary link to food selection and metabolic stress adaptation?

Authors:  Jürg Gertsch
Journal:  Br J Pharmacol       Date:  2017-01-16       Impact factor: 8.739

Review 5.  Impact of the Autonomic Nervous System on the Skeleton.

Authors:  Florent Elefteriou
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

Review 6.  The endocannabinoid system in cardiovascular function: novel insights and clinical implications.

Authors:  Salvador Sierra; Natasha Luquin; Judith Navarro-Otano
Journal:  Clin Auton Res       Date:  2017-12-08       Impact factor: 4.435

7.  Search for an endogenous cannabinoid-mediated effect in the sympathetic nervous system.

Authors:  Torsten Pfitzer; Nathalie Niederhoffer; Bela Szabo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-01-20       Impact factor: 3.000

8.  The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression.

Authors:  Nathalie Niederhoffer; Karin Schmid; Bela Szabo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-04-23       Impact factor: 3.000

Review 9.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 10.  The emerging role of the endocannabinoid system in cardiovascular disease.

Authors:  Pál Pacher; Sabine Steffens
Journal:  Semin Immunopathol       Date:  2009-04-09       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.